Insider Transactions in Q1 2022 at Adaptive Biotechnologies Corp (ADPT)
Insider Transaction List (Q1 2022)
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Mar 09
2022
|
Chad M Robins CEO and Chairman |
SELL
Open market or private sale
|
Direct |
14,815
-0.77%
|
$177,780
$12.46 P/Share
|
|
Mar 09
2022
|
Chad M Robins CEO and Chairman |
SELL
Exercise of conversion of derivative security
|
Direct |
14,815
-0.76%
|
$88,890
$6.32 P/Share
|
|
Mar 08
2022
|
Francis Lo Chief People Officer |
SELL
Open market or private sale
|
Direct |
3,582
-3.84%
|
$39,402
$11.44 P/Share
|
|
Mar 08
2022
|
Lance Baldo Chief Medical Officer |
SELL
Open market or private sale
|
Direct |
3,350
-16.32%
|
$36,850
$11.43 P/Share
|
|
Mar 08
2022
|
Stacy L Taylor SVP and General Counsel |
SELL
Open market or private sale
|
Direct |
2,387
-3.17%
|
$26,257
$11.44 P/Share
|
|
Mar 08
2022
|
Chad M Robins CEO and Chairman |
SELL
Open market or private sale
|
Direct |
14,815
-0.77%
|
$162,965
$11.38 P/Share
|
|
Mar 08
2022
|
Chad M Robins CEO and Chairman |
SELL
Exercise of conversion of derivative security
|
Direct |
14,815
-0.76%
|
$88,890
$6.32 P/Share
|
|
Mar 07
2022
|
Chad M Robins CEO and Chairman |
SELL
Open market or private sale
|
Direct |
19,239
-0.33%
|
$211,629
$11.92 P/Share
|
|
Mar 07
2022
|
Chad M Robins CEO and Chairman |
BUY
Exercise of conversion of derivative security
|
Direct |
14,815
+0.76%
|
$88,890
$6.32 P/Share
|
|
Mar 07
2022
|
Lance Baldo Chief Medical Officer |
SELL
Open market or private sale
|
Direct |
2,373
-10.37%
|
$28,476
$12.01 P/Share
|
|
Mar 07
2022
|
R Mark Adams Chief Operating Officer |
SELL
Open market or private sale
|
Direct |
1,244
-1.0%
|
$14,928
$12.01 P/Share
|
|
Mar 07
2022
|
Harlan S Robins Chief Scientific Officer |
SELL
Open market or private sale
|
Direct |
4,517
-1.43%
|
$54,204
$12.01 P/Share
|
|
Mar 07
2022
|
Francis Lo Chief People Officer |
SELL
Open market or private sale
|
Direct |
1,569
-1.66%
|
$18,828
$12.01 P/Share
|
|
Mar 07
2022
|
Kyle Piskel Chief Financial Officer |
SELL
Open market or private sale
|
Direct |
220
-0.46%
|
$2,640
$12.01 P/Share
|
|
Mar 07
2022
|
Stacy L Taylor SVP and General Counsel |
SELL
Open market or private sale
|
Direct |
1,569
-2.04%
|
$18,828
$12.01 P/Share
|
|
Mar 07
2022
|
Sharon Benzeno Chief Commercial Ofc Imm Med |
SELL
Open market or private sale
|
Direct |
2,670
-2.54%
|
$32,040
$12.01 P/Share
|
|
Mar 07
2022
|
Julie Rubinstein President |
SELL
Open market or private sale
|
Direct |
4,613
-2.0%
|
$55,356
$12.01 P/Share
|
|
Mar 04
2022
|
R Mark Adams Chief Operating Officer |
BUY
Grant, award, or other acquisition
|
Direct |
74,135
+37.23%
|
-
|
|
Mar 04
2022
|
Chad M Robins CEO and Chairman |
BUY
Grant, award, or other acquisition
|
Direct |
247,117
+11.4%
|
-
|
|
Mar 04
2022
|
Harlan S Robins Chief Scientific Officer |
BUY
Grant, award, or other acquisition
|
Direct |
247,117
+43.85%
|
-
|
|
Mar 04
2022
|
Francis Lo Chief People Officer |
BUY
Grant, award, or other acquisition
|
Direct |
74,135
+43.9%
|
-
|
|
Mar 04
2022
|
Kyle Piskel Chief Financial Officer |
BUY
Grant, award, or other acquisition
|
Direct |
41,186
+46.24%
|
-
|
|
Mar 04
2022
|
Stacy L Taylor SVP and General Counsel |
BUY
Grant, award, or other acquisition
|
Direct |
61,779
+44.58%
|
-
|
|
Mar 04
2022
|
Sharon Benzeno Chief Commercial Ofc Imm Med |
BUY
Grant, award, or other acquisition
|
Direct |
82,372
+43.9%
|
-
|
|
Mar 04
2022
|
Julie Rubinstein President |
BUY
Grant, award, or other acquisition
|
Direct |
185,338
+44.5%
|
-
|
|
Mar 04
2022
|
Nitin Sood Chief Commercial Officer, MRD |
BUY
Grant, award, or other acquisition
|
Direct |
65,898
+28.78%
|
-
|
|
Jan 26
2022
|
Leslie Trigg Director |
BUY
Grant, award, or other acquisition
|
Direct |
6,689
+37.53%
|
-
|
|
Jan 26
2022
|
Katey Einterz Owen Director |
BUY
Grant, award, or other acquisition
|
Direct |
6,689
+37.53%
|
-
|
|
Jan 26
2022
|
Peter M Neupert Director |
BUY
Grant, award, or other acquisition
|
Direct |
6,689
+44.95%
|
-
|
|
Jan 26
2022
|
Robert Hershberg Director |
BUY
Grant, award, or other acquisition
|
Direct |
6,689
+44.95%
|
-
|
|
Jan 26
2022
|
Michelle Renee Griffin Director |
BUY
Grant, award, or other acquisition
|
Direct |
6,689
+44.95%
|
-
|
|
Jan 26
2022
|
Kevin T Conroy Director |
BUY
Grant, award, or other acquisition
|
Direct |
6,689
+44.95%
|
-
|
|
Jan 26
2022
|
Michael J Pellini Director |
BUY
Grant, award, or other acquisition
|
Direct |
6,689
+44.95%
|
-
|
|
Jan 07
2022
|
R Mark Adams Chief Operating Officer |
SELL
Open market or private sale
|
Direct |
1,021
-1.97%
|
$23,483
$23.32 P/Share
|